Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy

Kyaw Zin Thein, Donald Paul Quick, Thura Win Htut, Lukman Tijani, Thein Hlaing Oo

Research output: Contribution to journalArticlepeer-review

1 Scopus citations

Abstract

Lung cancer (LC) is the leading cause of cancer mortality. PATP was provided in experimental trials to decrease the venous thromboembolism (VTE), with ultimate aim to improve overall survival (OS). We undertook an updated systematic review and meta-analysis of randomized controlled trials (RCTs) to determine the impact of PATP with LMWHs on OS and VTE in patients with LC. 5443 patients with LC from nine RCTs were included. The pooled hazard ratio (HR) for OS was 1.02 (95% CI 0.83 to 1.26; P = 0.83) and for progression or metastasis-free survival was 1.03 (95% CI 0.86 to 1.24; P = 0.74). The pooled risk ratio (RR) for VTE was 0.54 (95% CI 0.43 to 0.69; P < 0.00001) and the risk difference (RD) was—0.03 (− 0.05 to − 0.02; P < 0.00001). Our analysis showed no survival advantage with the addition of PATP with LMWHs to standard chemotherapy in patients with LC, regardless of histology or stages of small cell LC.

Original languageEnglish (US)
Pages (from-to)575-579
Number of pages5
JournalLung
Volume198
Issue number3
DOIs
StatePublished - Jun 1 2020
Externally publishedYes

Keywords

  • Lung cancer
  • Meta-analysis
  • Overall survival
  • Primary ambulatory thromboprophylaxis
  • Recurrence or metastasis-free survival

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Impact of Primary Ambulatory Thromboprophylaxis (PATP) with Low-Molecular Weight Heparins (LMWHs) on Survival in Patients with Lung Cancer Receiving Chemotherapy'. Together they form a unique fingerprint.

Cite this